康恩貝(600572.SH):ZY13提取物及片獲得藥物臨牀試驗批准通知書
格隆匯10月21日丨康恩貝(600572.SH)公佈,公司收到國家藥品監督管理局核准簽發的ZY13提取物及片的《藥物臨牀試驗批准通知書》。公司申請藥物臨牀試驗的ZY13片,適應症為陰虛火旺所致的年齡相關性黃斑變性,給藥途徑為口服給藥,註冊分類屬中藥1.2類新藥。最適用法用量待臨牀試驗結束後確認。本品已開展的藥效學實驗結果表明,ZY13提取物具有抑制脈絡膜血管新生的功效。截至目前,本公司對本品已投入研發費用約人民幣1,500萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.